Promising survival results were shown in the FORTE trial of carfilzomib plus lenalidomide, and dexamethasone induction/consolidation with autologous stem cell transplant and maintenance with carfilzomib-lenalidomide in patients with multiple myeloma.
Results from CC-220-MM-001 trial support further research of iberdomide-based regimens in multiple myeloma that investigators hope will lead to phase 3 randomized trials and eventual FDA approval of iberdomide in these combinations.
For the treatment of de novo metastatic castration-sensitive prostate cancer improved radiographic progression-free survival and overall survival was seen with the addition of prednisone to androgen-deprivation therapy plus docetaxel.
The frequency of moderate to severe cytokine release syndrome was reduced in patients with relapsed or refractory multiple myeloma who received anakinra prophylaxis with orvacabtagene autoleucel, a BCMA-targeted CAR T-cell therapy, according to findings presented at the European Hematology Association 2021 Virtual Congress.
Sustained overall survival and progression-free survival benefits was confirmed following long-term treatment with durvalumab following chemoradation in patients with unresectable stage 3 non-small cell lung cancer whose disease had not progressed after platinum-based concurrent chemoradiotherapy.